MX2016002307A - Tratamiento para el cancer. - Google Patents

Tratamiento para el cancer.

Info

Publication number
MX2016002307A
MX2016002307A MX2016002307A MX2016002307A MX2016002307A MX 2016002307 A MX2016002307 A MX 2016002307A MX 2016002307 A MX2016002307 A MX 2016002307A MX 2016002307 A MX2016002307 A MX 2016002307A MX 2016002307 A MX2016002307 A MX 2016002307A
Authority
MX
Mexico
Prior art keywords
cancer treatment
individual
cancer
treatment
trichostatin
Prior art date
Application number
MX2016002307A
Other languages
English (en)
Inventor
Louis William Licamele
H Polymeropoulos Mihael
Christian Lavedan
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2016002307A publication Critical patent/MX2016002307A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere en general al tratamiento del cáncer. Una modalidad de la invención proporciona un método de tratamiento de cáncer en un individuo, comprendiendo el método: administrar al individuo una cantidad eficaz de tricostatina A (TSA).
MX2016002307A 2013-08-22 2014-08-22 Tratamiento para el cancer. MX2016002307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22
PCT/US2014/052209 WO2015027121A2 (en) 2013-08-22 2014-08-22 Cancer treatment

Publications (1)

Publication Number Publication Date
MX2016002307A true MX2016002307A (es) 2016-06-15

Family

ID=51794948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002307A MX2016002307A (es) 2013-08-22 2014-08-22 Tratamiento para el cancer.

Country Status (12)

Country Link
US (5) US20160199323A1 (es)
EP (2) EP3616754A1 (es)
JP (4) JP2016528297A (es)
KR (5) KR20210127821A (es)
CN (2) CN105579101A (es)
AU (4) AU2014308700A1 (es)
CA (1) CA2921036A1 (es)
CL (1) CL2016000397A1 (es)
EA (1) EA037667B1 (es)
ES (1) ES2755983T3 (es)
MX (1) MX2016002307A (es)
WO (1) WO2015027121A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210127821A (ko) * 2013-08-22 2021-10-22 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료
WO2021016203A1 (en) * 2019-07-19 2021-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target
WO2023168201A1 (en) * 2022-03-01 2023-09-07 Vanda Pharmaceuticals Inc. Trichostatin a (tsa) sensitivity in the treatment of tumors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
CA1265431A (en) 1985-01-08 1990-02-06 Roderick John Macdonald Electrode device for flare stack ignitor
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
CA2529840A1 (en) * 2003-06-27 2005-01-06 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
ES2555994T3 (es) 2004-05-21 2016-01-12 The Board Of Trustees Of The University Of Arkansas System Uso de perfiles de expresión génica para predecir la supervivencia en un paciente con cáncer
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
CN101495111A (zh) 2006-05-26 2009-07-29 细胞基因公司 在联合治疗中使用免疫调节化合物的方法和组合物
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
TWI662964B (zh) * 2012-06-04 2019-06-21 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
KR20160033780A (ko) 2013-08-22 2016-03-28 반다 파마슈티칼즈, 인코퍼레이티드. 다발성 골수종 치료
KR20210127821A (ko) * 2013-08-22 2021-10-22 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료

Also Published As

Publication number Publication date
EA201690445A1 (ru) 2016-06-30
JP2021105005A (ja) 2021-07-26
US20180256522A1 (en) 2018-09-13
KR102315528B1 (ko) 2021-10-21
US11078289B2 (en) 2021-08-03
US20160199323A1 (en) 2016-07-14
US20230257471A1 (en) 2023-08-17
CN110585184A (zh) 2019-12-20
EA037667B1 (ru) 2021-04-28
KR20210127821A (ko) 2021-10-22
WO2015027121A3 (en) 2015-05-14
CL2016000397A1 (es) 2017-03-17
EP3036007A2 (en) 2016-06-29
AU2021261882B2 (en) 2022-04-14
AU2022202183A1 (en) 2022-04-21
AU2019261718A1 (en) 2019-11-28
US11667718B2 (en) 2023-06-06
KR20230047203A (ko) 2023-04-06
KR20160033779A (ko) 2016-03-28
AU2014308700A1 (en) 2016-02-25
ES2755983T3 (es) 2020-04-24
KR20210013343A (ko) 2021-02-03
KR20170126018A (ko) 2017-11-15
US10265282B2 (en) 2019-04-23
NZ716668A (en) 2021-02-26
CA2921036A1 (en) 2015-02-26
AU2022202183B2 (en) 2023-09-28
JP2016528297A (ja) 2016-09-15
US20190211107A1 (en) 2019-07-11
US20210324093A1 (en) 2021-10-21
JP2019167351A (ja) 2019-10-03
EP3036007B1 (en) 2019-10-09
CN105579101A (zh) 2016-05-11
JP2023088996A (ja) 2023-06-27
WO2015027121A2 (en) 2015-02-26
AU2021261882A1 (en) 2021-12-02
EP3616754A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
PH12015502075A1 (en) Treatment of cataplexy
HK1219486A1 (zh) 用於治療癌症的涉及抗密蛋白 的抗體的療法
HK1213925A1 (zh) 用於治療癌症的涉及抗密蛋白 抗體的組合療法
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
EP2944323A4 (en) MEANS FOR THE TREATMENT OF TUMORS, USE AND METHOD THEREFOR
MX2015014590A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
NZ722600A (en) Methods of treating mild brain injury
MX2017000306A (es) Metodos para tratar hipotension.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2016002308A (es) Tratamiento del mieloma multiple.
PH12014502065A1 (en) Vesicular formulations
MX2016002307A (es) Tratamiento para el cancer.
RS63738B1 (sr) Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
BR112016014099A2 (pt) método de tratamento de feridas
SI2976360T1 (sl) Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka
MX2017013669A (es) Composiciones para el tramiento del cancer.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
UA86338U (ru) Способ лечения беременных с гестационным диабетом